New insights on ocular surface disease in patients with atopic dermatitis treated with dupilumab

New insights on ocular surface disease in patients with atopic dermatitis treated with dupilumab

Our study sought to describe ocular surface alterations at baseline and after 4 months of dupilumab treatment in patients with severe AD. Our findings highlight that all 25 patients showed ocular surface alterations prior to dupilumab treatment. Dupilumab may cause the worsening of clinical or subcl...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:British journal of dermatology (1951) 2022-01, Vol.186 (1), p.186-187
Hauptverfasser: Bortoluzzi, P., Ferrucci, S., Galimberti, D., Garavelli, F., Pozzo Giuffrida, F., Pizzati, A., Marzano, A.V., Mapelli, C.
Format: Artikel
Sprache:eng
Schlagworte:
Antibodies, Monoclonal, Humanized - adverse effects
Atopic dermatitis
Dermatitis, Atopic - drug therapy
Eczema
Eczema - drug therapy
Humans
Monoclonal antibodies
Patients
Severity of Illness Index
Treatment Outcome
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Our study sought to describe ocular surface alterations at baseline and after 4 months of dupilumab treatment in patients with severe AD. Our findings highlight that all 25 patients showed ocular surface alterations prior to dupilumab treatment. Dupilumab may cause the worsening of clinical or subclinical pre‐existing ocular alterations belonging to the spectrum of AKC.
ISSN:0007-0963
1365-2133
DOI:10.1111/bjd.20706